1. In Vivo
  2. >>Innovation

IXICO Targets Go-To Status In Neuro Data Analytics Space

 
• By Ashley Yeo

Neuroscience data specialist IXICO has broad ambitions to partner with pharmas large and small, helping them develop better-targeted clinical trials using imaging and digital biomarker data. A business review in late 2017 by CEO Giulio Cerroni refined the company’s value proposition, while keeping the headline elements in place: scale the business and diversify within neuroscience.

Cerroni_Giulio
IXICO CEO Giulio Cerroni

The neuroscience data analytics company Ixico Ltd. is many things to many people, but it is not a start-up. CEO of two years Giulio Cerroni stresses that almost before we start. IXICO is also not an especially young company, formed some 14 years ago as a spin-out from several UK universities, it has been trading for 13 years, and in 2018 (year-end September 30) reported an underlying revenue increase of 41% and a record-high revenue total of £5.4m ($7.02m). It has been AIM-listed since its 2013 reverse takeover of Phytopharm.

The company’s performance to date has been good, but it is not good enough for Cerroni. On assuming the chief...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates

 
• By David Wild

With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.

How Annexon Reclaimed Its Geographic Atrophy Program After Phase II Miss

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Rising Leaders 2025: Noam Solomon’s Quest To Create A ‘Google Maps’ Of the Immune System

 
• By David Wild

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.

Three Approaches, One Goal: How Digital Twin Technologies Can Differ

 
• By David Wild

Three digital twin approaches compete: image-based precision, phenotypic modeling and massive data aggregation.

More from In Vivo

How Annexon Reclaimed Its Geographic Atrophy Program After Phase II Miss

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Deals Shaping The Industry, August 2025

An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.

Rising Leaders 2025: Noam Solomon’s Quest To Create A ‘Google Maps’ Of the Immune System

 
• By David Wild

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.